2026-04-13T02:27:43Zhttps://recercat.cat/oai/request
oai:recercat.cat:2072/4791652025-10-05T13:25:34Zcom_2072_98col_2072_378192
RECERCAT author Jimenez-Fonseca, Paula author Foy, Victoria author Raby, Sophie author Carmona-Bayonas, Alberto author Macía-Rivas, Lola author Arrazubi, Virginia author Cacho Lavin, Diego author Hernandez San Gil, Raquel author Custodio, Ana author Cano, Juana María author Fernández Montes, Ana author Mirallas, Oriol author Macias Declara, Ismael author Vidal Tocino, Rosario author Visa, Laura author Limón, María Luisa author Pimentel, Paola author Martínez Lago, Nieves author Saurí Nadal, Tamara author Martín Richard, Marta author Mangas, Monserrat author Gil Raga, Mireia author Calvo, Aitana author Reguera, Pablo author Granja, Mónica author Martín Carnicero, Alfonso author Hernández Pérez, Carolina author Cerdà, Paula author Gomez Gonzalez, Lucía author Garcia Navalon, Francisco author Pacheco-Barcia, Vilma author Gutierrez Abad, David author Ruiz Martín, Maribel author Weaver, Jamie author Mansoor, Wasat author Gallego, Javier author Universitat Autònoma de Barcelona 2023 Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints. open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by-nc/4.0/ HER2-positive Gastric cancer Nomogram Oesophageal cancer Survival Trastuzumab The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy Article